Pacira BioSciences (PCRX) Depreciation & Amortization (CF) (2016 - 2025)
Pacira BioSciences has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $21.3 million for Q4 2025.
- Quarterly results put Depreciation & Amortization (CF) at $21.3 million for Q4 2025, changed 0.47% from a year ago — trailing twelve months through Dec 2025 was $91.0 million (up 15.53% YoY), and the annual figure for FY2025 was $91.0 million, up 15.53%.
- Depreciation & Amortization (CF) for Q4 2025 was $21.3 million at Pacira BioSciences, up from $21.2 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for PCRX hit a ceiling of $30.4 million in Q4 2022 and a floor of $4.9 million in Q1 2021.
- Median Depreciation & Amortization (CF) over the past 5 years was $19.8 million (2022), compared with a mean of $18.3 million.
- Biggest five-year swings in Depreciation & Amortization (CF): soared 326.06% in 2022 and later tumbled 39.21% in 2023.
- Pacira BioSciences' Depreciation & Amortization (CF) stood at $13.1 million in 2021, then soared by 132.64% to $30.4 million in 2022, then crashed by 39.21% to $18.5 million in 2023, then increased by 14.92% to $21.2 million in 2024, then increased by 0.47% to $21.3 million in 2025.
- The last three reported values for Depreciation & Amortization (CF) were $21.3 million (Q4 2025), $21.2 million (Q3 2025), and $27.3 million (Q2 2025) per Business Quant data.